Strides Pharma Science’s step-down wholly owned subsidiary, Strides Pharma Global Pte. Singapore, has received approval for sodium sulphate, potassium sulphate and magnesium sulphate oral solution 17.5g/ 3.13g/ 1.6g per 6 ounces (product) from the United States Food & Drug Administration (FDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug, Suprep Bowel Prep Kit oral solution 17.5g/ 3.13g/ 1.6g per 6 ounces of Braintree Laboratories Inc. (Braintree). The approval bolsters the company's portfolio of products in bowel preparation that spans both prescription and over the counter offerings.
The company has 260 cumulative ANDA filings including the recently acquired portfolio from Endo at Chestnut Ridge) with US FDA, of which 230+ ANDAs have been approved. The company has set a target to launch ~ 60 new products over three years in the US.
The product belongs to a group of medicines prescribed to those who are required to undergo a colon cleanse prior to a colonoscopy. The kit is available in a carton containing two 6 ounce bottles of the liquid and a mixing container.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!